Aptevo Therapeutics (Aptevo Therapeutics) Margin of Safety % (DCF Earnings Based) : N/A (As of Apr. 27, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Aptevo Therapeutics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Aptevo Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

Competitive Comparison of Aptevo Therapeutics's Margin of Safety % (DCF Earnings Based)

For the Biotechnology subindustry, Aptevo Therapeutics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptevo Therapeutics's Margin of Safety % (DCF Earnings Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Aptevo Therapeutics's Margin of Safety % (DCF Earnings Based) falls into.

Aptevo Therapeutics Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Aptevo Therapeutics's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptevo Therapeutics (Aptevo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptevo Therapeutics Inc (NAS:APVO) » Definitions » Margin of Safety % (DCF Earnings Based)

Comparable Companies

Traded in Other Exchanges

AP8N:Germany

Address

2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121

Website

https://www.aptevotherapeutics.com

Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Executives

Daphne Taylor	officer: SVP, CFO	3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Kevin C Tang	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Soyoung Kwon	officer: See Remarks	APTEVO THERAPEUTICS INC., 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Randy Joe Maddux	officer: Senior VP, Operations	2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Fuad El-hibri	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Daniel Abdun-nabi	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Marvin L White	director, officer: President and CEO	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Barbara Lopez Kunz	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Zsolt Harsanyi	director	2273 RESEARCH BLVD., SUITE 400, ROCKVILLE MD 20850
Grady Iii Grant	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Shawnte Mitchell	officer: SVP, GC and Corporate Affairs	5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael Adelman	officer: SVP, Commercial Operations	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Jane A Gross	officer: See Remarks	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121